Artificial intelligence and medical technology company Echo IQ (ASX: EIQ) has cited US commercialisation plans and ongoing clinical studies for its EchoSolv heart disease screening platform as its main areas of focus for the three months to December 2022.
In a large, real-world cohort undergoing routine echocardiography, an artificial intelligence decision-support algorithm identified patients with moderate to severe forms of aortic stenosis associated with poor survival if left untreated.Surgical and transcatheter aortic valve replacement are associated with mortality reduction across all aortic stenosis subgroups, yet data show fewer than half
A new analysis of the data on severe aortic stenosis reveals that the potential demand from undiagnosed patients exceeds NHS capacity to screen or treat the disease.